Brief: Knight Therapeutics Announces Filling Of Supplement To A New Drug Submission For Nerlynx®
03/09/2020 22:42
Sept 3 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES FILLING OF SUPPLEMENT TO A
NEW
DRUG SUBMISSION FOR NERLYNX® (NERATINIB) TO TREAT HER2-POSITIVE
METASTATIC BREAST CANCER
* KNIGHT THERAPEUTICS INC - SNDS FOR NERLYNX IS SUPPORTED BY
RESULTS OF PHASE III NALA TRIAL
Source text for Eikon: ID:nGNX4Hnb4D
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil